Impact Factor: 3,34
Abstracts will be published in
Journal of Biotechnology

Confirmed Speakers

Dr. Anna Zajakina

Dr. Anna Zajakina is a leader of Cancer Gene therapy group at Latvian Biomedical Research and Study Centre. The group is specializes in development of clinically translatable methods for cancer treatment based on gene therapy vectors and combination of different strategies including chemotherapy and immunotherapy. The group uses a wide variety of alphaviral vectors as promising candidates for transient intratumoral delivery of therapeutic genes. Currently, the group leads two collaborative projects focused on delivery of alphaviral RNA into tumor, using classical way through infection with recombinant virus (i) and alternative way through viral RNA delivery by magnetic nanoparticles and polyfunctional pyridinium amphiphiles (ii). Moreover, the group has a strong interest in unraveling fine mechanisms of alphavirus infection and identification of factors of tumor microenvironment for efficient targeting of cancer cells.

<< back